Calidi Biotherapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Basic
Calidi Biotherapeutics, Inc. (CLDI) reported Net Income (Loss) Available to Common Stockholders, Basic of -$4.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2026-08-13
- Calidi Biotherapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-06-30 was -$4.16M.
- Calidi Biotherapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2026-03-31 was -$4.42M.
- Calidi Biotherapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-12-31 was -$4.06M.
- Calidi Biotherapeutics, Inc. net income (loss) available to common stockholders, basic for the quarter ending 2025-09-30 was -$10.82M.
- Calidi Biotherapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2025 was -$25.58M.
- Calidi Biotherapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2024 was -$23.81M.
- Calidi Biotherapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2023 was -$29.22M, a 2827.06% decline from fiscal 2022.
- Calidi Biotherapeutics, Inc. net income (loss) available to common stockholders, basic for fiscal 2022 was $1.07M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.16M 10-Q · filed 2026-08-13 | -$8.58M 10-Q · filed 2026-08-13 | -$12.63M derived: sum of 3 quarters · filed 2026-08-13 | -$23.45M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2026-03-31 | -$4.42M 10-Q · filed 2026-05-14 | -$8.47M derived: sum of 2 quarters · filed 2026-05-14 | -$19.30M derived: sum of 3 quarters · filed 2026-05-14 | -$25.01M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-12-31 | -$4.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$14.88M derived: sum of 2 quarters · filed 2026-03-27 | -$20.59M derived: sum of 3 quarters · filed 2026-08-13 | -$25.58M 10-K · filed 2026-03-27 | ||
| 2025-09-30 | -$10.82M 10-Q · filed 2025-11-13 | -$16.54M derived: sum of 2 quarters · filed 2026-08-13 | -$21.52M 10-Q · filed 2025-11-13 | -$25.62M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-06-30 | -$5.71M 10-Q · filed 2026-08-13 | -$10.70M 10-Q · filed 2026-08-13 | -$14.80M derived: sum of 3 quarters · filed 2026-08-13 | -$19.85M derived: sum of 4 quarters · filed 2026-08-13 | ||
| 2025-03-31 | -$4.99M 10-Q · filed 2026-05-14 | -$9.08M derived: sum of 2 quarters · filed 2026-05-14 | -$14.14M derived: sum of 3 quarters · filed 2026-05-14 | -$21.57M derived: sum of 4 quarters · filed 2026-05-14 | ||
| 2024-12-31 | -$4.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | -$9.15M derived: sum of 2 quarters · filed 2026-03-27 | -$16.59M derived: sum of 3 quarters · filed 2026-03-27 | -$23.81M 10-K · filed 2026-03-27 | ||
| 2024-09-30 | -$5.05M 10-Q · filed 2025-11-13 | -$12.49M derived: sum of 2 quarters · filed 2025-11-13 | -$19.72M 10-Q · filed 2025-11-13 | -$27.95M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$7.44M 10-Q · filed 2025-08-08 | -$14.66M 10-Q · filed 2025-08-08 | -$22.89M derived: sum of 3 quarters · filed 2025-08-08 | -$24.92M derived: sum of 4 quarters · filed 2025-08-08 | ||
| 2024-03-31 | -$7.22M 10-Q · filed 2025-05-14 | -$15.45M derived: sum of 2 quarters · filed 2025-05-14 | -$17.48M derived: sum of 3 quarters · filed 2025-05-14 | -$29.98M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$8.23M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$10.25M derived: sum of 2 quarters · filed 2025-03-31 | -$22.75M derived: sum of 3 quarters · filed 2025-03-31 | -$29.22M 10-K · filed 2025-03-31 | ||
| 2023-09-30 | -$2.02M 10-Q · filed 2024-11-12 | -$14.53M derived: sum of 2 quarters · filed 2024-11-12 | -$20.99M 10-Q · filed 2024-11-12 | -$20.56M derived: sum of 4 quarters · filed 2024-11-12 | ||
| 2023-06-30 | -$12.50M 10-Q · filed 2024-08-13 | -$4.58M 10-Q · filed 2023-08-21 | -$18.96M 10-Q · filed 2024-08-13 | -$7.25M 10-Q · filed 2023-08-21 | -$18.54M derived: sum of 3 quarters · filed 2024-08-13 | -$19.55M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$2.68M 10-Q · filed 2023-05-15 | -$6.04M derived: sum of 2 quarters · filed 2023-05-15 | -$7.05M derived: sum of 3 quarters · filed 2023-05-15 | -$3.05M derived: sum of 4 quarters · filed 2023-08-21 | ||
| 2022-12-31 | -$3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | -$4.37M derived: sum of 2 quarters · filed 2023-03-31 | -$372.08K derived: sum of 3 quarters · filed 2023-08-21 | $1.07M 10-K · filed 2023-03-31 | ||
| 2022-09-30 | -$1.01M 10-Q · filed 2022-11-14 | $2.99M derived: sum of 2 quarters · filed 2023-08-21 | $4.43M 10-Q · filed 2022-11-14 | $8.72M derived: sum of 4 quarters · filed 2023-08-21 | ||
| 2022-06-30 | $4.00M 10-Q · filed 2023-08-21 | $5.44M 10-Q · filed 2023-08-21 | $9.73M derived: sum of 3 quarters · filed 2023-08-21 | -$22.73M derived: sum of 4 quarters · filed 2023-08-21 | ||
| 2022-03-31 | $1.44M 10-Q · filed 2023-05-15 | $5.73M derived: sum of 2 quarters · filed 2023-05-15 | -$26.73M derived: sum of 3 quarters · filed 2023-05-15 | |||
| 2021-12-31 | $4.29M derived: 10-K 9 month − 10-Q 6 month · filed 2023-03-31 | -$28.17M derived: sum of 2 quarters · filed 2023-03-31 | -$28.25M 10-K · filed 2023-03-31 | |||
| 2021-09-30 | -$32.46M 10-Q · filed 2022-11-14 | -$20.97M 10-Q · filed 2021-11-12 | -$32.54M 10-Q · filed 2022-11-14 | -$21.05M 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| CURIS INC (CRIS) | United States | $0.002B | -0.05 |
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |